NCT00264017

Brief Summary

In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2005

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2005

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2005

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 6, 2005

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 12, 2005

Completed
Last Updated

December 12, 2005

Status Verified

November 1, 2005

First QC Date

December 6, 2005

Last Update Submit

December 6, 2005

Conditions

Prostate Cancer Patients Undergoing External Radiation and Seed Implantation

Eligibility Criteria

Age45 Years - 80 Years
Sexmale
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males age 45-80 years
  • Diagnosis of prostate cancer
  • Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation
  • Baseline AUA score\< or =12
  • May be on antiandrogenand/or alpha reductase therapy
  • Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent -

You may not qualify if:

  • History of insulin-dependent diabetes
  • Uncontrolled hypertention
  • History of symptomtic hypotension (including syncope and dizziness)
  • Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary Retention
  • Pre-existing prostatitis either continuous or intermittent
  • Concurrent use of any other anticholinergics
  • previous or concurrent usage of LHRH agonist

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dattoli Cancer Center and Brachytherapy Research Institute

Sarasota, Florida, 34237, United States

Location

Study Officials

  • Michael J Dattoli, MD

    Dattoli Cancer Center and Brachytherapy Research Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 6, 2005

First Posted

December 12, 2005

Study Start

November 1, 2005

Study Completion

November 1, 2005

Last Updated

December 12, 2005

Record last verified: 2005-11

Locations

US(1)